CoChat
Sign Up
Cited by 230Cannabis and Cannabinoid ResearchPain Mechanisms and TreatmentsPain Management and Treatment

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats

Petrosino, Stefania, Palazzo, Enza, de Novellis, Vito, Bisogno, Tiziana, Rossi, Francesco, Maione, Sabatino, Di Marzo, Vincenzo·2007·Neuropharmacology
DOI 10.1016/j.neuropharm.2006.08.011
Open this paper in CoChat — free account

Abstract

Recent studies have shown that activation of the cannabinoid CB(1) receptor by synthetic agonists, and pharmacological elevation of endocannabinoid levels, suppress hyperalgesia and allodynia in animal models of neuropathic pain. However, the concentrations of endocannabinoids in the nervous tissues involved in pain transmission during neuropathic pain have never been measured. Here we have determined the levels of anandamide and 2-arachidonoylglycerol (2-AG), as well as of the analgesic anandamide congener, palmitoylethanolamide (PEA), in three brain areas involved in nociception, i.e. the dorsal raphe (DR), periaqueductal grey (PAG) and rostral ventral medulla (RVM), as well as in the spinal cord (SC), following chronic constriction injury (CCI) of the sciatic nerve in the rat, in comparison with sham-operated rats. After 3 days from CCI, anandamide or 2-AG levels were significantly enhanced only in the SC or PAG, respectively. After 7 days from CCI, when thermal hyperalgesia and mechanical allodynia are maximal, a strong (1.3-3-fold) increase of both anandamide and 2-AG levels was observed in the PAG, RVM and SC. At this time point, anandamide, but not 2-AG, levels were also enhanced in the DR. PEA levels were significantly decreased in the SC after 3 days, and in the DR and RVM after 7 days from CCI. These data indicate that anandamide and 2-AG, operating at both spinal and supra-spinal levels, are up-regulated during CCI of the sciatic nerve, possibly to inhibit pain. Yet to be developed substances that inhibit both endocannabinoid and PEA inactivation might be useful for the treatment of neuropathic pain.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2006.08.011

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 46 references

Research works printed but not linked: 2

  1. Costa, B., Colleoni, M., Trovato, A.E., Conti, S., Pomelli, F., Franke, C., 2005. Anandamide uptake and hydrolysis as targets for the treatment of neuropathic pain: effect of AM404 and URB597 in rats with chronic constriction injury of the sciatic nerve. XV Symposium on the Cannabinoids, Clearwater Beach, FL, 24–29 June 2005, p. 33.
  2. Costa, B., Comelli, F., Colleoni, M., Giagnoni, G., 2006. Effect of CB1/TRPV1 agonist, arvanil, in acute inflammation and in persistent inflammatory and neuropathic pain. XVI Symposium on the Cannabinoids, Tihany, Hungary, 24–29 June 2006, p. 38.

Cited by

Sorted by citations

Items 201–230 of 230

Related

See all

Metadata

Authors
Petrosino, S., Palazzo, E., de Novellis, V., Bisogno, T., Rossi, F., Maione, S., & Di Marzo, V.
Affiliations
  • Istituto di Chimica Biomolecolare (IT)
  • University of Campania "Luigi Vanvitelli" (IT)
ORCID
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2007-02
Volume
52
Issue
2
Pages
415-422
ISSN
0028-3908 (ISSN-L)
DOI
10.1016/j.neuropharm.2006.08.011
OpenAlex
W2061301719
Cited by
227
References
46
Citations by year
2026: 4 · 2025: 9 · 2024: 5 · 2023: 5 · 2022: 12 · 2021: 7 · 2020: 16 · 2019: 10 · 2018: 7 · 2017: 14 · 2016: 7 · 2015: 14 · 2014: 11 · 2013: 18 · 2012: 15
FWCI
10.03
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Neuropharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
Keywords
endocannabinoids, neuropathic pain, anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, chronic constriction injury, sciatic nerve, spinal cord, dorsal raphe nucleus, periaqueductal gray, rostral ventrolateral medulla, thermal hyperalgesia, mechanical allodynia, CB1 receptor, analgesia
MeSH terms
Analysis of Variance, Animals, Behavior, Animal, Disease Models, Animal, Male, Pain Measurement, Reaction Time, Sciatica, Mass Spectrometry, Spinal Cord, Time Factors, Rats, Wistar, Rats, Cannabinoid Receptor Modulators, Endocannabinoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review